12:00 AM
 | 
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zelboraf vemurafenib regulatory update

The U.K.'s NICE said it needs additional information before it can recommend the use of Zelboraf vemurafenib from Roche to treat patients with unresectable locally advanced or metastatic melanoma who are BRAF V600-mutation positive. NICE is asking for clarification on the assumptions made in a new economic model that Roche submitted after the committee's June recommendation against Zelboraf. The...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >